How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema.

ABSTRACT:

Background

Intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular oedema (DME) may begin with several initial monthly doses. Characteristics, treatment patterns and outcomes were compared for eyes with DME that did and did not receive such initial doses.

Methods

This was a retrospective database study using American Academy of Ophthalmology Intelligent Research in Sight^® Registry data (01/01/15-31/12/20; index period). Eligible adults had documented DME within 2 months of first anti-VEGF treatment (index date), data available for 12 months beforehand, and ≥ 1 visual acuity (VA) recording ≤ 60 days before index date. Eyes must have received intravitreal anti-VEGF injections during the index period, but none in the prior 12 months

SUBMITTER: Singh RP 

PROVIDER: S-EPMC11684133 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature